Alzamend Neuro (ALZN) Payables (2020 - 2026)

Alzamend Neuro has disclosed Payables across 7 years of filings, most recently posting $1.3 million for Q2 2026.

• In Q2 2026, Payables rose 112.07% year-over-year to $1.3 million; the TTM figure through Apr 2026 stood at $1.3 million (up 112.07% YoY), while the FY2026 annual figure was $1.3 million, up 112.07% from the prior year.
• Payables came in at $1.3 million for Q2 2026 at Alzamend Neuro, down from $1.9 million in the prior quarter.
• In the past five years, Payables ranged from a high of $3.8 million in Q1 2024 to a low of $466977.0 in Q1 2022.
• Average Payables over 5 years is $1.9 million, with a median of $1.5 million recorded in 2022.
• Year-over-year, Payables soared 465.87% in 2023 and tumbled 81.03% in 2025.
• Over 5 years, Payables stood at $1.6 million in 2022, then jumped by 123.89% to $3.7 million in 2023, then sank by 65.77% to $1.3 million in 2024, then sank by 42.82% to $717488.0 in 2025, then soared by 87.62% to $1.3 million in 2026.
• Per Business Quant data, the three most recent Payables figures were $1.3 million in Q2 2026, $1.9 million in Q1 2026, and $717488.0 in Q4 2025.